Add like
Add dislike
Add to saved papers

Neonatal thyroid function after administration of IV iodinated contrast agent to 21 pregnant patients.

OBJECTIVE: The objective of our study was to document neonatal thyroid function after in utero exposure to nonionic iodinated contrast material to determine the potential risk of subsequent neonatal hypothyroidism.

MATERIALS AND METHODS: We identified pregnant patients ("maternal patient") who underwent CT with iodinated IV contrast material between February 2000 and October 2006. The specifics of the CT examinations were reviewed including patient age, gestational age of conceptus at time of exposure, type of CT, and type and dose of contrast agent. The neonatal serum thyroid-stimulating hormone (TSH) level obtained from the exposed infant ("neonatal patient") was retrieved from the Minnesota Department of Health.

RESULTS: Twenty-one patients gave us consent to review the requested data concerning their 23 children (two mothers had twins). Mean maternal age at the time of CT was 29 years (range, 19-41 years). Mean gestational age (based on last menstrual period) at the time of CT was 23 weeks (range, 8-37 weeks). Neonatal patients were born at a mean of 38 weeks of gestation (range, 24-41 weeks of gestation). Serum TSH was collected at a mean of 43 hours after delivery (range, 24-70 hours). For all neonatal patients, serum TSH levels were normal. Mean serum TSH was 9.7 muIU/mL (range, 2.2-28.8 muIU/mL). No maternal patient reported thyroid trouble in her child.

CONCLUSION: Based on neonatal TSH measurements in a small number of patients, we found no ill effect of iodinated contrast agents on neonatal thyroid function after in utero exposure.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app